title: Comment on: Mannucci, P. M. Evolution of the European guidelines for the clinical development of factor VIII products.
authors.affiliation: Paul-Ehrlich-Institut, Langen, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Hilger
authors.forename: C
authors.initials: C
authors.lastname: Arras-Reiter
authors.forename: B
authors.initials: B
authors.lastname: Keller-Stanislawski
authors.forename: B
authors.initials: B
authors.lastname: Ljungberg
authors.forename: C
authors.initials: C
authors.lastname: Male
authors.forename: D
authors.initials: D
authors.lastname: Mentzer
authors.forename: R
authors.initials: R
authors.lastname: Seitz
authors.forename: G
authors.initials: G
authors.lastname: Silvester
mesh_terms: D005169:Factor VIII / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans
chemical_list: D005169:Factor VIII